#United States #Orlando #Nanoscope Therapeutics #Vision Restoration #MCO platform

Nanoscope Therapeutics to Showcase Innovative Therapies at AAO 2025

Nanoscope Therapeutics Inc., a pioneering biotechnology firm, is preparing for significant presentations at the American Academy of Ophthalmology (AAO) Annual Meeting 2025. This prestigious event will take place from October 18 to 20, 2025, in the vibrant city of Orlando, Florida. During this meeting, Nanoscope aims to highlight its cutting-edge Multi-Characteristic Opsin (MCO) platform, which offers hope to individuals suffering from photoreceptor loss and vision impairments caused by retinal degeneration.

Event Highlights and Presentation Schedule

Key Presentations:

1. Nanoscope Therapeutics Company Showcase
- Date/Time: October 16, 2025, from 1:40 PM to 1:45 PM EDT
- Location: W230
- Presenter: Dr. Samuel Barone, Chief Medical Officer

2. 152-Week REMAIN Data from Extended Analysis of MCO-010 RESTORE Study
- Date/Time: October 18, 2025, from 8:11 AM to 8:18 AM EDT
- Location: W415 Valencia
- Presenter: Dr. Allen C. Ho, Attending Surgeon and Director of Retina Research at Wills Eye Hospital; Chief Medical Advisor at Nanoscope

3. Visual Improvement with MCO-010 Therapy in Stargardt Disease
- Date/Time: October 18, 2025, from 1:45 PM to 2:15 PM EDT
- Location: Hall WB4, Station 1
- Presenter: Dr. Kenneth C. Fan, Retina Consultants of Texas

4. Optogenetic Therapy in Adults with Retinitis Pigmentosa and Stargardt Disease
- Date/Time: October 20, 2025, from 8:30 AM to 8:45 AM EDT
- Location: W311E
- Presenters: Dr. Samarendra Mohanty, President and CSO at Nanoscope; Dr. Stephen Tsang, Columbia University

Clinical Significance

Nanoscope is eager to present the latest findings on its MCO platform at the AAO meeting. As emphasized by CEO Sulagna Bhattacharya, these presentations are vital for showcasing the robust clinical and regulatory framework that supports their therapies, particularly the rolling Biologics License Application (BLA) for retinitis pigmentosa (RP). Moreover, recent designations by the European Medicines Agency underscore Nanoscope’s commitment to advancing the care for patients grappling with blinding retinal diseases.

Understanding the MCO Platform

The MCO platform represents a groundbreaking, one-time intravitreal therapy designed to restore vision even in patients suffering from significant retinal degeneration. This innovative approach is applicable to a range of conditions, including retinitis pigmentosa, Stargardt disease, and geographic atrophy. The MCO technology enhances the sensitivity of remaining retinal cells to light, effectively utilizing the existing visual pathways after photoreceptor loss. Importantly, this therapy circumvents the need for genetic testing, invasive procedures, or multiple treatments, thus simplifying administration within standard retina practices.

About Nanoscope Therapeutics

Nanoscope Therapeutics is at the forefront of developing vision-restoring therapies for patients affected by retinal diseases. Following encouraging results from the RESTORE Phase 2b/3 clinical trial for RP, Nanoscope is actively pursuing a rolling BLA submission to the FDA. The aim is to establish MCO-010 as the new standard of care for RP patients, executed via a convenient one-time, in-office injection. Moreover, promising trial outcomes in Stargardt disease, coupled with plans for a Phase 3 study in 2025, emphasize the company’s dynamic approach to the treatment landscape for retinal degenerative conditions.

In conclusion, Nanoscope Therapeutics is poised to make a significant impact at the AAO 2025, shedding light on the promising potential of their MCO platform in restoring vision and improving patient outcomes. The event promises to be a crucial opportunity to discuss advancements in eye health and innovative therapeutic solutions.